See more : New Technology Acquisition Holdings (NTAC) Income Statement Analysis – Financial Results
Complete financial analysis of Elekta AB (publ) (EKTA-B.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elekta AB (publ), a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- PMV Consumer Acquisition Corp. (PMVC-UN) Income Statement Analysis – Financial Results
- SecUR Credentials Limited (SECURCRED.BO) Income Statement Analysis – Financial Results
- Estun Automation Co., Ltd (002747.SZ) Income Statement Analysis – Financial Results
- Guizhou Aviation Technical Development Co., Ltd (688239.SS) Income Statement Analysis – Financial Results
- Jarllytec Co. , Ltd. (3548.TWO) Income Statement Analysis – Financial Results
Elekta AB (publ) (EKTA-B.ST)
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.12B | 16.87B | 14.55B | 13.76B | 14.60B | 13.56B | 11.33B | 10.70B | 11.22B | 10.84B | 10.69B | 10.34B | 9.05B | 7.90B | 7.39B | 6.69B | 5.08B | 4.53B | 4.42B | 3.15B | 2.90B | 2.78B | 2.74B |
| Cost of Revenue | 11.34B | 10.52B | 9.11B | 8.15B | 8.46B | 7.88B | 6.58B | 6.28B | 6.61B | 6.53B | 6.05B | 5.56B | 4.83B | 4.24B | 3.99B | 3.66B | 2.90B | 2.58B | 2.52B | 1.90B | 1.78B | 1.76B | 1.70B |
| Gross Profit | 6.78B | 6.35B | 5.44B | 5.61B | 6.14B | 5.68B | 4.75B | 4.43B | 4.61B | 4.31B | 4.65B | 4.78B | 4.22B | 3.67B | 3.41B | 3.03B | 2.18B | 1.94B | 1.90B | 1.25B | 1.12B | 1.02B | 1.04B |
| Gross Profit Ratio | 37.40% | 37.64% | 37.37% | 40.76% | 42.03% | 41.90% | 41.90% | 41.36% | 41.11% | 39.73% | 43.45% | 46.25% | 46.61% | 46.39% | 46.08% | 45.31% | 42.94% | 42.92% | 43.02% | 39.66% | 38.52% | 36.79% | 37.98% |
| Research & Development | 1.40B | 1.42B | 1.37B | 1.49B | 1.66B | 1.59B | 1.10B | 1.02B | 1.07B | 952.00M | 866.00M | 715.00M | 604.00M | 552.00M | 535.00M | 485.00M | 383.00M | 332.00M | 293.00M | 208.00M | 218.00M | 148.00M | 144.00M |
| General & Administrative | 1.37B | 1.40B | 1.17B | 1.09B | 1.09B | 1.04B | 948.00M | 928.00M | 1.03B | 1.05B | 918.00M | 878.00M | 754.00M | 749.00M | 708.00M | 642.00M | 498.00M | -190.00M | -210.00M | -120.00M | 291.00M | 285.00M | 315.00M |
| Selling & Marketing | 1.64B | 1.60B | 1.36B | 1.14B | 1.44B | 1.30B | 1.21B | 1.17B | 1.34B | 1.34B | 1.06B | 1.15B | 1.08B | 957.00M | 970.00M | 933.00M | 679.00M | 595.00M | 580.00M | 395.00M | 375.00M | 356.00M | 367.00M |
| SG&A | 3.01B | 3.00B | 2.53B | 2.23B | 2.54B | 2.34B | 2.16B | 2.09B | 2.36B | 2.38B | 1.97B | 2.03B | 1.84B | 1.71B | 1.68B | 1.58B | 1.18B | 405.00M | 370.00M | 275.00M | 666.00M | 641.00M | 682.00M |
| Other Expenses | 0.00 | 0.00 | 48.00M | 85.00M | -11.00M | -23.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00M | 4.00M | -34.00M | -30.00M | -14.00M | -46.00M | -67.00M | 24.00M |
| Operating Expenses | 4.76B | 4.48B | 3.95B | 3.80B | 4.18B | 3.90B | 3.25B | 3.11B | 3.43B | 3.34B | 2.84B | 2.74B | 2.44B | 2.26B | 2.21B | 2.20B | 1.56B | 1.54B | 1.34B | 1.11B | 838.00M | 722.00M | 850.00M |
| Cost & Expenses | 16.08B | 15.00B | 13.06B | 11.95B | 12.65B | 11.78B | 9.84B | 9.39B | 10.04B | 9.87B | 8.89B | 8.30B | 7.27B | 6.50B | 6.20B | 5.86B | 4.46B | 4.12B | 3.86B | 3.01B | 2.62B | 2.48B | 2.55B |
| Interest Income | 108.00M | 78.00M | 42.00M | 29.00M | 63.00M | 65.00M | 66.00M | 31.00M | 37.00M | 25.00M | 22.00M | 32.00M | 45.00M | 26.00M | 6.00M | 23.00M | 108.00M | 46.00M | 28.00M | 22.00M | 43.00M | 37.00M | 36.00M |
| Interest Expense | 482.00M | 226.00M | 148.00M | 233.00M | 214.00M | 156.00M | 163.00M | 209.00M | 240.00M | 217.00M | 202.00M | 223.00M | 200.00M | 58.00M | 50.00M | 107.00M | 76.00M | 71.00M | 59.00M | 15.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.14B | 1.06B | 1.04B | 1.20B | 1.26B | 943.00M | 675.00M | 655.00M | 634.00M | 512.00M | 414.00M | 349.00M | 295.00M | 241.00M | 229.00M | 208.00M | 176.00M | 136.00M | 171.00M | 81.00M | 88.00M | 72.00M | 63.00M |
| EBITDA | 3.29B | 2.57B | 2.74B | 3.14B | 2.99B | 2.70B | 2.58B | 1.28B | 1.10B | 1.45B | 2.16B | 2.40B | 2.20B | 1.76B | 1.47B | 1.09B | 866.00M | 697.00M | 659.00M | 467.00M | 367.00M | 373.00M | 253.00M |
| EBITDA Ratio | 18.16% | 14.74% | 18.48% | 22.28% | 20.16% | 19.80% | 19.64% | 16.09% | 14.80% | 13.36% | 21.31% | 23.39% | 24.22% | 22.31% | 19.90% | 16.28% | 15.63% | 15.78% | 15.25% | 15.04% | 12.66% | 13.41% | 9.24% |
| Operating Income | 2.04B | 1.43B | 1.64B | 1.91B | 1.66B | 1.70B | 1.54B | 598.00M | 423.00M | 937.00M | 1.73B | 2.01B | 1.85B | 1.50B | 1.23B | 830.00M | 650.00M | 509.00M | 453.00M | 364.00M | 306.00M | 323.00M | 207.00M |
| Operating Income Ratio | 11.25% | 8.48% | 11.29% | 13.85% | 11.35% | 12.51% | 13.57% | 5.59% | 3.77% | 8.64% | 16.15% | 19.46% | 20.44% | 19.00% | 16.67% | 12.41% | 12.79% | 11.25% | 10.25% | 11.55% | 10.55% | 11.61% | 7.56% |
| Total Other Income/Expenses | -371.00M | -233.00M | -142.00M | -276.00M | -435.00M | -198.00M | -123.00M | -976.00M | -997.00M | -255.00M | -225.00M | -212.00M | -141.00M | 49.00M | -40.00M | -56.00M | -26.00M | -19.00M | -9.00M | 7.00M | 19.00M | -6.00M | 14.00M |
| Income Before Tax | 1.67B | 1.20B | 1.50B | 1.63B | 1.45B | 1.58B | 1.37B | 340.00M | 189.00M | 716.00M | 1.50B | 1.80B | 1.71B | 1.46B | 1.19B | 774.00M | 624.00M | 507.00M | 444.00M | 378.00M | 325.00M | 317.00M | 221.00M |
| Income Before Tax Ratio | 9.21% | 7.10% | 10.32% | 11.84% | 9.96% | 11.66% | 12.12% | 3.18% | 1.68% | 6.61% | 14.05% | 17.41% | 18.88% | 18.52% | 16.13% | 11.57% | 12.28% | 11.20% | 10.04% | 11.99% | 11.21% | 11.40% | 8.07% |
| Income Tax Expense | 365.00M | 254.00M | 345.00M | 377.00M | 370.00M | 382.00M | 276.00M | 214.00M | 44.00M | 158.00M | 350.00M | 449.00M | 480.00M | 433.00M | 359.00M | 228.00M | 218.00M | 161.00M | 140.00M | 125.00M | -77.00M | -88.00M | -78.00M |
| Net Income | 1.30B | 943.00M | 1.15B | 1.25B | 1.08B | 1.20B | 1.10B | 125.00M | 137.00M | 552.00M | 1.15B | 1.34B | 1.23B | 1.03B | 833.00M | 546.00M | 406.00M | 348.00M | 304.00M | 253.00M | 248.00M | 234.00M | 145.00M |
| Net Income Ratio | 7.19% | 5.59% | 7.93% | 9.11% | 7.42% | 8.84% | 9.70% | 1.17% | 1.22% | 5.09% | 10.73% | 12.96% | 13.56% | 13.04% | 11.27% | 8.16% | 7.99% | 7.69% | 6.88% | 8.03% | 8.55% | 8.41% | 5.30% |
| EPS | 3.41 | 2.47 | 3.02 | 3.28 | 2.84 | 3.14 | 2.88 | 0.33 | 0.36 | 1.45 | 3.01 | 3.52 | 3.26 | 2.76 | 2.27 | 1.50 | 1.12 | 0.93 | 0.81 | 0.64 | 0.64 | 0.61 | 0.39 |
| EPS Diluted | 3.41 | 2.47 | 3.02 | 3.28 | 2.84 | 3.14 | 2.88 | 0.33 | 0.36 | 1.45 | 3.00 | 3.52 | 3.23 | 2.73 | 2.25 | 1.50 | 1.11 | 0.93 | 0.80 | 0.64 | 0.64 | 0.60 | 0.38 |
| Weighted Avg Shares Out | 382.08M | 382.08M | 382.08M | 382.08M | 382.08M | 382.03M | 382.03M | 381.31M | 381.29M | 381.29M | 381.28M | 380.67M | 376.43M | 373.36M | 368.83M | 368.12M | 368.80M | 374.79M | 376.54M | 375.96M | 391.02M | 384.23M | 372.58M |
| Weighted Avg Shares Out (Dil) | 382.09M | 382.37M | 382.08M | 382.08M | 382.08M | 382.03M | 382.03M | 381.31M | 381.29M | 381.29M | 400.69M | 380.67M | 380.13M | 378.03M | 371.78M | 368.12M | 369.92M | 377.00M | 379.12M | 376.73M | 391.02M | 392.33M | 390.05M |
Source: https://incomestatements.info
Category: Stock Reports